ResearcherKyushu UniversityActive in the last 2 years
Shuang Fei
Known by name at one institution; no external author ID yet. Sources: OpenAlex.
Their work
- Papers
- 3
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 20
2023: 1 paper · 2024: 1 paper · 2025: 1 paper
Papers 3
- Cadherin 23 is a prognostic marker of pancreatic cancer and promotes cell viability in floating culture conditions. Co-author DOI 10.7150/ijms.98252↗
- Dynamic glycolytic reprogramming effects on dendritic cells in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13046-024-03192-8↗
- Involvement of angiogenesis in cancer-associated acinar-to-ductal metaplasia lesion of pancreatic cancer invasive front. Co-author DOI 10.1007/s00432-022-04554-5↗
Closest collaborators
The 20 strongest of 20 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Chika Iwamoto · 2 shared papers, 2023–2024 · strength 0.34
- Yoshinao Oda · 2 shared papers, 2023–2024 · strength 0.34
- Bo Zhang · 2 shared papers, 2023–2024 · strength 0.34
- Kohei Nakata · 2 shared papers, 2023–2024 · strength 0.34
- Kenoki Ohuchida · 2 shared papers, 2023–2024 · strength 0.34
- Naoki Ikenaga · 2 shared papers, 2023–2024 · strength 0.34
- Chaohui Zhen · 1 shared paper, 2025 · strength 0.25
- Biao Zheng · 1 shared paper, 2025 · strength 0.25
- Chikanori Tsutsumi · 1 shared paper, 2024 · strength 0.18
- Masafumi Nakamura · 1 shared paper, 2024 · strength 0.18
- Nan Sheng · 1 shared paper, 2024 · strength 0.18
- Koki Oyama · 1 shared paper, 2024 · strength 0.18
- Yuki Mochida · 1 shared paper, 2024 · strength 0.18
- Koji Shindo · 1 shared paper, 2024 · strength 0.18
- Shin Kibe · 1 shared paper, 2023 · strength 0.16
- Zilong Yan · 1 shared paper, 2023 · strength 0.16
- Masafumi Nakamura · 1 shared paper, 2023 · strength 0.16
- Toshiya Abe · 1 shared paper, 2023 · strength 0.16
- Noboru Ideno · 1 shared paper, 2023 · strength 0.16
- Tomohiko Shinkawa · 1 shared paper, 2023 · strength 0.16
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.